Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Cancer Research

Executive Summary: Anlotinib hydrochloride (SKU: C8688, APExBIO) is a small-molecule inhibitor with high specificity for VEGFR2, PDGFRβ, and FGFR1, showing IC₅₀ values in the low nanomolar range under in vitro conditions (APExBIO product documentation). It exhibits robust anti-angiogenic effects, including inhibition of VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary tube formation (Chen & Feng 2019, DOI). Pharmacokinetic studies report rapid oral absorption, high plasma protein binding (93% in humans), and significant tissue distribution, including the ability to cross the blood-brain barrier. Comparative benchmarks indicate enhanced potency over sunitinib, sorafenib, and nintedanib in relevant cell-based and animal models. Safety profiles show a high LD₅₀ with minimal organ or genetic toxicity in preclinical studies.

Biological Rationale

Angiogenesis is a critical process for tumor growth and metastasis. Inhibiting angiogenic signaling pathways, especially those mediated by vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs), is a validated strategy for cancer therapy (Chen & Feng 2019). Anlotinib hydrochloride is designed to target multiple receptor tyrosine kinases involved in tumor angiogenesis and progression, making it suitable for dissecting complex signaling networks in cancer models. This multi-target approach addresses resistance mechanisms that often limit single-target agents (Anlotinib Hydrochloride: Advanced Multi-Target Tyrosine Kinase Inhibitor). This article updates prior mechanistic reviews by providing new quantitative and workflow integration data.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib (hydrochloride) inhibits the kinase activities of VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively, measured in cell-free enzymatic assays at 25°C in Tris buffer (pH 7.5) (APExBIO). This inhibition blocks phosphorylation cascades and downstream ERK signaling, reducing endothelial cell migration and tube formation in vitro. Anlotinib also inhibits c-Kit and Met, extending its anti-angiogenic and anti-tumor spectrum (Chen & Feng 2019). Compared to sunitinib and sorafenib, anlotinib demonstrates broader target coverage and higher potency in both cell-based and xenograft models. Pharmacokinetic studies in rats and dogs show oral bioavailability of 28%–58% and 41%–77%, respectively, with high membrane permeability and 93% plasma protein binding in humans. The drug is metabolized primarily by CYP3A, producing hydroxylated and dealkylated metabolites, and is widely distributed in lung, liver, kidney, heart, and tumor tissues.

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary-like tube formation at nanomolar concentrations in EA.hy 926 cell assays (APExBIO, product page).
• IC₅₀ values for VEGFR2, PDGFRβ, and FGFR1 are 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively, outperforming sunitinib and sorafenib in comparative studies (Chen & Feng 2019).
• Preclinical PK: Oral bioavailability in rats (28–58%) and dogs (41–77%); high tissue distribution and BBB permeability (APExBIO).
• Phase I clinical evidence: Demonstrated anti-tumor activity in colon adenocarcinoma, non-small-cell lung cancer, renal cell carcinoma, and medullary thyroid carcinoma (Chen & Feng 2019, Table 1).
• High LD₅₀ (1735.9 mg/kg, 14-day oral, mouse), with mild and manageable systemic toxicity; no significant organ/genetic toxicity in preclinical models (APExBIO).

For a systems biology perspective on anlotinib’s unique multi-target effects, see this analysis; this article provides updated workflow integration and new comparative benchmarks.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily used in preclinical cancer research to study tumor angiogenesis, cell migration, and signaling pathway modulation. It is recommended for use in cellular assays with human vascular endothelial cells (e.g., EA.hy 926) and in vivo tumor models. Researchers employ anlotinib in capillary tube formation assays and endothelial migration experiments to quantify anti-angiogenic effects. Its broad kinase inhibition profile makes it suitable for dissecting complex signaling interactions and resistance mechanisms within cancer models (Redefining Tumor Angiogenesis Inhibition—this article extends those findings with quantitative PK/PD data and integration tips).

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Anlotinib hydrochloride (SKU C8688) is supplied for research applications only and is not approved for human therapeutic use (APExBIO).
• Single-agent limitations: While anlotinib inhibits multiple kinase pathways, tumors with alternative angiogenic drivers or intrinsic resistance mechanisms may not respond (Chen & Feng 2019).
• Assay conditions matter: Efficacy and potency are highly dependent on assay pH, temperature, and cell type; always match published protocols.
• Metabolic considerations: Metabolite profiles may differ across species due to varying CYP3A activity; cross-species extrapolation requires caution.
• Off-target effects: At high concentrations, anlotinib may affect additional kinases beyond the primary targets; titrate doses carefully.

Workflow Integration & Parameters

Anlotinib hydrochloride integrates into angiogenesis and cytotoxicity research workflows as a benchmark inhibitor in endothelial cell migration and tube formation assays. Recommended storage is at -20°C in a desiccated environment. For cell-based assays, concentrations typically range from 1 nM to 1 μM, with exposure times of 24–72 hours. Pre-dilute stocks in DMSO and avoid repeated freeze-thaw cycles. For in vivo studies, oral administration is preferred, with dosing adjusted based on species-specific PK data. The compound's high plasma protein binding and wide tissue distribution must be considered in experimental design (Reliable Solutions for Angiogenesis Assays; this article details quantitative integration parameters for C8688).

For troubleshooting and advanced assay strategies, see Enhancing Tumor Angiogenesis Assays with Anlotinib—this guide is complemented here with updated potency benchmarks and PK data.

Conclusion & Outlook

Anlotinib hydrochloride (APExBIO SKU C8688) is a validated, high-potency multi-target tyrosine kinase inhibitor for advanced cancer and angiogenesis research. It offers robust, reproducible inhibition of key angiogenic pathways, with superior selectivity and safety profiles in preclinical settings. Its broad applicability in cellular and in vivo models, combined with comprehensive supporting data, makes it a preferred tool for dissecting tumor angiogenesis and optimizing translational research workflows (Chen & Feng 2019). Future research may further clarify its role in combination regimens and resistance mechanisms.

For detailed product specifications and ordering information, visit the Anlotinib (hydrochloride) product page.